Physician profile
Erik Aragon
NPI 1770585556
$5,186.11
in general payments reported to CMS, 2019-2025
31 companies · $386 in 2025
The $386 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,131 · 2020: $605 · 2021: $830 · 2022: $686 · 2023: $957 · 2024: $592 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,934.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $790.11 | 2019-2025 | |
| Biogen, INC. | $661.20 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Emd Serono, INC. | $572.02 | 2019-2025 | Mavenclad |
| Ucb, INC. | $374.06 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Teva Pharmaceuticals USA, INC. | $362.00 | 2019-2021 | |
| Lilly USA, LLC | $340.16 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Abbvie INC. | $294.14 | 2021-2024 | Ubrelvy, Qulipta |
| Eisai INC. | $245.94 | 2020-2025 | |
| Genentech USA, INC. | $189.81 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Genzyme Corporation | $160.76 | 2019-2024 | |
| Acadia Pharmaceuticals INC | $150.89 | 2019-2023 | Nuplazid |
| Argenx US, INC. | $127.13 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
| Csl Behring | $97.58 | 2019-2023 | Hizentra |
| Mallinckrodt Hospital Products INC. | $83.64 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $72.03 | 2019-2023 | Ultomiris |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $69.72 | 2019-2025 | Vns Therapy |
| Allergan, INC. | $69.17 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $67.35 | 2020-2025 | |
| Lundbeck LLC | $65.15 | 2019-2024 | Rexulti, Vyepti |
| Ge Healthcare | $60.83 | 2020-2023 | |
| Acorda Therapeutics, INC | $56.77 | 2019-2023 | Inbrija, Ampyra |
| Amgen INC. | $45.23 | 2019 | |
| Bausch Health US, LLC | $41.12 | 2019 | |
| Pfizer INC. | $30.80 | 2024 | |
| Amneal Pharmaceuticals LLC | $30.41 | 2020-2025 | Crexont |
| Celgene Corporation | $27.90 | 2022 | |
| Grifols USA, LLC | $25.12 | 2021-2022 | |
| Mdd US Operations, LLC | $21.94 | 2024 | Gocovri |
| Akcea Therapeutics, INC. | $21.66 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $19.20 | 2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $12.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Aragon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.